688382 Stock Overview
A clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InventisBio Co., Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.72 |
| 52 Week High | CN¥18.41 |
| 52 Week Low | CN¥6.50 |
| Beta | 0.14 |
| 11 Month Change | 7.67% |
| 3 Month Change | -22.88% |
| 1 Year Change | -42.64% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688382 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 8.9% | 3.9% | 0.8% |
| 1Y | -42.6% | -23.8% | -21.0% |
Return vs Industry: 688382 underperformed the CN Biotechs industry which returned -23.8% over the past year.
Return vs Market: 688382 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 688382 volatility | |
|---|---|
| 688382 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688382's share price has been volatile over the past 3 months.
Volatility Over Time: 688382's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 221 | Yaolin Wang | www.inventisbio.com |
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications.
InventisBio Co., Limited Fundamentals Summary
| 688382 fundamental statistics | |
|---|---|
| Market cap | CN¥4.45b |
| Earnings (TTM) | -CN¥249.28m |
| Revenue (TTM) | CN¥194.13m |
22.4x
P/S Ratio-17.5x
P/E RatioIs 688382 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688382 income statement (TTM) | |
|---|---|
| Revenue | CN¥194.13m |
| Cost of Revenue | CN¥4.04m |
| Gross Profit | CN¥190.09m |
| Other Expenses | CN¥439.37m |
| Earnings | -CN¥249.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 97.92% |
| Net Profit Margin | -128.41% |
| Debt/Equity Ratio | 0% |
How did 688382 perform over the long term?
See historical performance and comparison